📊 ACONW Key Takeaways
Is Aclarion, Inc. (ACONW) a Good Investment?
Aclarion is a pre-revenue medical laboratory services company with severe operational losses and minimal commercialization progress. Despite holding substantial cash reserves relative to its small asset base, the company is burning capital rapidly with -$7.2M operating cash flow on just $75.7K in revenue, indicating the business model has not achieved product-market fit. The near-total absence of profitability metrics and inability to generate positive cash flow make this a highly speculative venture-stage company unsuitable for fundamental investors.
Aclarion shows severe fundamental weakness: revenue remains negligible at $75.73K while operating and net losses exceed $7M, producing extremely negative margins and deeply negative free cash flow. Although the balance sheet is currently clean with $12.02M in cash, no long-term debt, and strong liquidity, the business is not demonstrating scalable commercial traction, so its cash position appears to be funding ongoing losses rather than supporting a proven operating model.
Why Buy Aclarion, Inc. Stock? ACONW Key Strengths
- Strong cash position ($12.0M) provides 15+ months of runway at current burn rate
- Minimal leverage (0.00x debt-to-equity) eliminates solvency risk in near term
- Exceptional liquidity ratios (14.81x current ratio) allow operational flexibility
- Strong liquidity with $12.02M in cash and 14.81x current ratio
- Debt-free balance sheet with minimal liabilities relative to equity
- Revenue grew 65.6% YoY, showing some top-line improvement from a low base
ACONW Stock Risks: Aclarion, Inc. Investment Risks
- Catastrophic operating losses (-$7.1M) on minimal revenue ($75.7K) indicates failed commercialization
- Negative free cash flow of -$7.2M unsustainable without additional capital raises or revenue acceleration
- Medical laboratory sector requires significant regulatory approval and customer validation that company has not demonstrated
- Cash burn trajectory suggests funding runway exhaustion without material revenue growth
- No insider purchases in 90 days suggests lack of confidence from company leadership
- Revenue base is far too small to support the cost structure, with operating margin of -9312.5%
- Cash burn is very high, with operating cash flow of -$7.16M and free cash flow of -$7.19M
- Growth quality is weak because losses remain massive despite revenue growth, indicating limited commercialization progress
Key Metrics to Watch
- Revenue growth rate and path to positive unit economics
- Monthly cash burn rate and projected runway duration
- Operating cash flow inflection toward breakeven
- Customer acquisition metrics and contract pipeline
- Regulatory approvals or clinical validation milestones
- Quarterly revenue growth versus operating expense growth
- Cash burn runway based on operating cash flow and ending cash balance
Aclarion, Inc. (ACONW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.81x current ratio provides a solid financial cushion.
ACONW Profit Margin, ROE & Profitability Analysis
ACONW vs Healthcare Sector: How Aclarion, Inc. Compares
How Aclarion, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aclarion, Inc. Stock Overvalued? ACONW Valuation Analysis 2026
Based on fundamental analysis, Aclarion, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aclarion, Inc. Balance Sheet: ACONW Debt, Cash & Liquidity
ACONW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aclarion, Inc.'s revenue has grown significantly by 25% over the 5-year period, indicating strong business expansion. The most recent EPS of $-7,478.90 indicates the company is currently unprofitable.
ACONW Revenue Growth, EPS Growth & YoY Performance
ACONW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $14.4K | -$1.2M | $-2.93 |
| Q2 2025 | $11.0K | -$1.2M | $-2.75 |
| Q1 2025 | $10.1K | -$2.0M | $-9.32 |
| Q3 2024 | $14.4K | -$998.0K | $-0.15 |
| Q2 2024 | $11.0K | -$1.2M | $-0.15 |
| Q1 2024 | $10.1K | -$1.2M | $-0.44 |
| Q3 2023 | $18.2K | -$936.1K | $-0.12 |
| Q2 2023 | $10.7K | -$936.1K | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aclarion, Inc. Dividends, Buybacks & Capital Allocation
ACONW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aclarion, Inc. (CIK: 0001635077)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACONW
What is the AI rating for ACONW?
Aclarion, Inc. (ACONW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACONW's key strengths?
Claude: Strong cash position ($12.0M) provides 15+ months of runway at current burn rate. Minimal leverage (0.00x debt-to-equity) eliminates solvency risk in near term. ChatGPT: Strong liquidity with $12.02M in cash and 14.81x current ratio. Debt-free balance sheet with minimal liabilities relative to equity.
What are the risks of investing in ACONW?
Claude: Catastrophic operating losses (-$7.1M) on minimal revenue ($75.7K) indicates failed commercialization. Negative free cash flow of -$7.2M unsustainable without additional capital raises or revenue acceleration. ChatGPT: Revenue base is far too small to support the cost structure, with operating margin of -9312.5%. Cash burn is very high, with operating cash flow of -$7.16M and free cash flow of -$7.19M.
What is ACONW's revenue and growth?
Aclarion, Inc. reported revenue of $75.7K.
Does ACONW pay dividends?
Aclarion, Inc. does not currently pay dividends.
Where can I find ACONW SEC filings?
Official SEC filings for Aclarion, Inc. (CIK: 0001635077) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACONW's EPS?
Aclarion, Inc. has a diluted EPS of $-13.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACONW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Aclarion, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACONW stock overvalued or undervalued?
Valuation metrics for ACONW: ROE of -56.4% (sector avg: 15%), net margin of -9,551.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ACONW stock in 2026?
Our dual AI analysis gives Aclarion, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACONW's free cash flow?
Aclarion, Inc.'s operating cash flow is $-7.2M, with capital expenditures of $21.5K. FCF margin is -9,488.6%.
How does ACONW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9,551.9% (avg: 12%), ROE -56.4% (avg: 15%), current ratio 14.81 (avg: 2).